Our clinical research infrastructures are where the patients are

To tackle the real problems in clinical research, we invest in new, stable, professional infrastructures called Clinical Research Units (CRUs) directly at healthcare institutions.

Crossover is establishing dozens of CRUs to manage the clinical research activities of its affiliated healthcare institutions. It offers superior enrolment with minimal cohort attrition since it is closely associated with the clinical research process through its CRUs which are directly embedded at healthcare institutions.

In addition to setting-up and staffing the CRUs, Crossover provides additional support through its regional/national subsidiaries, including human resources, financial, administrative, legal and technical support.

We invest where the patients are.

Outline of the Crossover model

• All the services of an SMO (Site management organisation) with its own network of Clinical Trials Units at medical institutions
  
  • Permanent Clinical Research Unit (CRU) embedded at the healthcare institution
  • International Crossover network (COCRIN) of research-minded leading healthcare institutions
  • Uniform clinical research SOPs and training at the healthcare institution
  • Central business development
  • Central support: clinical operations, clinical research and hospital information systems and technical support (products, samples and supplies)
• All the services of a CRO
  
  • Clinical trials from protocol to final integrated report
  • Clinical trials from phase I – IV

For further information about our clinical research services, please contact Jean-Pierre Tassignon, President & CEO (Jean-Pierre.Tassignon@crossover-cri.com).

The Crossover model benefits sponsors

• One-stop shop
• Better prepared healthcare facilities
• More objective feasibility studies
• Lower monitoring costs
• Cleaner data available earlier
• Access to EHR database statistics
• Experienced project management
• Cost-effective
• EDC, EMR
• Crossover Executive Committee members and consultants have world-class pharmaceutical industry and CRO experience

The Crossover model benefits the healthcare institution and investigators

• Growing revenue stream: more clinical trials, more patients, more investment (public and private)
• Better utilisation of all departments
• Less hassle (feasibilities, budgets and contracts, invoicing, project flow, data entry, research compliance, etc. is carried out by the CRU)
• The Crossover partner brings know-how, investment, staff and business development
• Improved training/coaching
• Better financial control of research activities
• Professional global marketing
• Risks of the CRU are shared with a competent partner
• Accreditation of hospital
• More publications – and thus greater visibility
• More international connections (conferences and investigator meetings)
• Higher levels of job satisfaction among doctors and nurses
• More attractive to new high-calibre staff
• Greater attractiveness to patients